The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Otrivine Extra Dual Relief 0.5mg/ml + 0.6mg/ml nasal spray, solution

0.5mg /ml + 0.6mg/ml milligram(s)/millilitre Nasal spray, solution

GlaxoSmithKline Consumer Healthcare (Ireland) LimitedPA0678/131/001

Main Information

Trade NameOtrivine Extra Dual Relief 0.5mg/ml + 0.6mg/ml nasal spray, solution
Active SubstancesXylometazoline hydrochloride
Ipratropium bromide
Strength0.5mg /ml + 0.6mg/ml milligram(s)/millilitre
Dosage FormNasal spray, solution
Licence HolderGlaxoSmithKline Consumer Healthcare (Ireland) Limited
Licence NumberPA0678/131/001

Group Information

ATC CodeR01AB Sympathomimetics, combinations excl. corticosteroids
R01AB06 xylometazoline

Status

Authorised/WithdrawnAuthorised
Licence Issued18/12/2012
Legal statusProduct not subject to medical prescription
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to the general public
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back